Drug Discovery & DDS– category –
-
Drug Discovery & DDS
Drug Discovery & DDS Weekly Report May 31, 2026
📄 Weekly Report May 31, 2026 (PDF) — Download Weekly Report May 31, 2026 (PDF) — DownloadDownload 🎙 Podcast May 31, 2026 (MP3) — Play & Download DrugDiscovery_DDSEnglishPodcast_20260531.mp3Download -
Drug Discovery & DDS
Regulatory & Policy Shifts Reshape Global Biologics Manufacturing Strategy: Focus on EU Reform, UK Decentralization, and US Tariffs
IMAPAC UK Overview Regulatory and policy shifts, including EU Pharma Reform, UK decentralized manufacturing initiatives, and U.S. tariffs, are fundamentally reshaping global biologics manufacturing strategies. Notably, the UK has establi... -
Drug Discovery & DDS
US Department of Veterans Affairs Launches MDMA-Assisted Mental Health Therapy Trial
VA News (US Department of Veterans Affairs) USA Overview The U.S. Department of Veterans Affairs (VA) has initiated a clinical trial for MDMA-assisted mental health therapy, following the FDA's Breakthrough Therapy designation for MDMA, ... -
Drug Discovery & DDS
WuXi Biologics Intensifies Focus on South Korea to Bolster K-Biotech Partnerships Amid US Pressure
BioCentury (Chosun Biz) South Korea Overview WuXi Biologics is expanding its sales efforts in South Korea, actively targeting K-biotech companies amidst increasing U.S. legislative scrutiny on Chinese biotech firms. As a major global Con... -
Drug Discovery & DDS
WuXi Biologics Shanghai Drug Product Facility Achieves GMP Release, Expands Global Capacity
Contract Pharma China Overview WuXi Biologics' Drug Product Facility 15 (DP15) in Shanghai secured Good Manufacturing Practice (GMP) release in April 2026, becoming its 18th operational drug product facility globally. This state-of-the-a... -
Drug Discovery & DDS
FDA Approves Hepcludex, First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
FDA (Press Release), European AIDS Treatment Group USA Overview The U.S. FDA has approved Hepcludex (bulevirtide-gmod) injection as the first treatment for chronic hepatitis delta virus (HDV) infection in adults, with or without compensa... -
Drug Discovery & DDS
Tuning siRNA Packing Order in Lipid Nanoparticles Controls Oligonucleotide Functional Delivery
bioRxiv (Preprint) International Overview This preprint investigates how tuning the siRNA packing order within lipid nanoparticles (LNPs) can modulate oligonucleotide functional delivery, addressing a key challenge in RNA therapeutics: e... -
Drug Discovery & DDS
Insilico Medicine and Saudi Aramco Unveil ‘Sanity Pipeline’ for AI-Driven MOF Discovery
Insilico Medicine (Press Release), ChemRxiv (Preprint reference) Hong Kong Overview Insilico Medicine and Saudi Aramco have introduced the "Sanity Pipeline," an innovative AI-driven tool designed to tackle structural validity challenges ... -
Drug Discovery & DDS
CVS Caremark Expands Access to Eli Lilly’s Obesity Portfolio: Reinstates Zepbound, Adds Foundayo
FirstWord Pharma USA Overview CVS Caremark announced it will reinstate coverage for Eli Lilly's injectable weight-loss medication Zepbound (tirzepatide) and add the newly launched oral GLP-1 drug Foundayo (orforglipron) to its standard c... -
Drug Discovery & DDS
Daiichi Sankyo Unveils Extensive Oncology Portfolio Progress at ASCO; Datopotamab Deruxtecan Approved for First-Line mTNBC
Daiichi Sankyo (Press Release), MedCity News, ADC Review, FirstWord Pharma Japan Overview Daiichi Sankyo will present over 25 abstracts at the 2026 ASCO Annual Meeting, showcasing its leading oncology portfolio, including new clinical da...